利拉鲁肽在胰岛素抵抗2型糖尿病患者中应用的临床观察

Clinical Application Observation of Liraglutide in Insulin Resistance in Patients with Type 2 Diabetes

目的利拉鲁肽在胰岛素抵抗的2型糖尿病患者应用的临床疗效观察。方法选取2014年6月至2015年6月在大连港医院内分泌科就诊的80例胰岛素抵抗的2型糖尿病患者,随机分为对照组40例,采取二甲双胍治疗;试验组40例使用二甲双胍联合皮下注射利拉鲁肽治疗,比较两组患者治疗2周后比较空腹血糖、餐后血糖、GA的变化,12周后比较糖化血红蛋白变化情况。结果试验组各项指标均优于对照组,差异有统计学意义(P<0.05)。讨论对胰岛素抵抗的2型糖尿病患者采用二甲双胍联合皮下注射利拉鲁肽的治疗方法,可明显降低其餐后血糖、空腹血糖,降低糖化血红蛋白,值得在临床推广。

Objective Liraglutidc in insulin resistance in patients with type 2 diabetes clinical curative effect observation of application. Methods Selection in June 2014 to June 2015 in Dalian port hospital endocrinology clinic of 80 patients with insulin resistance of type 2 diabetes mellitus, 40 patients were randomly divided into test group, taking metformin treatment. The control group 40 cases with metformin subcutaneously liraglutidc treatment. Compare two groups of patients 2 weeks after fasting plasma glucose, postprandial blood sugar, the change of the GA, 12 weeks after the comparison of HbAlC changes. Results Test group were superior to control group, the difference was statistically significant （P 〈 0.05）. Conclusion For insulin resistance in patients with type 2 diabetes with metformin in combination with subcutaneous injections, liraglutidc treatment, can obviously reduce the postprandial blood glucose, fasting blood sugar, reduce glycated hemoglobin, is worth popularizing in clinical.